Real-World Effectiveness of Dupilumab in Patients With Prurigo Nodularis: An Observational Study
This study is an important look at how a medicine called dupilumab works for people who have prurigo nodularis, a skin condition causing very itchy bumps. It's an "observational study," meaning researchers are watching what happens in real life, rather than giving out new treatments. They want to find out how effective dupilumab is for managing this condition over time. They're also gathering information about the people taking dupilumab and how the medicine is being used. This information will help doctors understand more about treating prurigo nodularis with dupilumab in a real-world setting.
At a glance
What is this study about?
This study is about a skin condition called prurigo nodularis (PN), which causes very itchy, bumpy skin. The study focuses on a medicine called dupilumab, and how well it works for people with PN in their everyday lives. It's an "observational study," which means doctors are simply watching patients who are already prescribed dupilumab for their PN. They're not trying out a new medicine or giving specific instructions on how to use it beyond what's usually prescribed. This helps them understand how the medicine works in typical healthcare situations, outside of strict research settings.
The main goal is to see how dupilumab is being used for PN in different countries and how effective it is over a longer period. The researchers want to learn about the health backgrounds of people taking dupilumab for PN, their social details, and how their PN affects them. They will also look at how well dupilumab helps improve their condition over time. This kind of information is really helpful for doctors to understand the benefits and patterns of treatment for PN.
By collecting all this information, researchers hope to get a clearer picture of living with PN and how dupilumab helps manage it across various patients and healthcare systems. It helps provide 'real-world' evidence that can support patients and doctors in making informed decisions about treatment.
Key takeaways
- This study looks at how dupilumab helps people with prurigo nodularis in everyday life.
- It's an 'observational' study, meaning no new treatments are given.
- Researchers want to understand dupilumab's effectiveness and how it's used.
- Participation involves sharing information about your health and treatment.
- You'll be followed for around 18 months.
- Your standard medical care will not change if you participate.
Who may be eligible?
To be able to take part in this study, you must be 18 years old or older. You also need to have been prescribed dupilumab for your prurigo nodularis by your doctor before you decided to join the study. This means your doctor chose this treatment for you as part of your usual care, not specifically for the study. You also need to be able to understand and fill out some questionnaires related to the study and agree to participate willingly.
You cannot join the study if your doctor thinks you have a medical reason that makes dupilumab unsuitable for you, or if you have any other condition (like a very short life expectancy or severe memory problems) that would make it difficult for you to complete the study visits and assessments. You also can't take part if you are already in another clinical trial where you're receiving a specific treatment. Finally, if you've used dupilumab in the last six months, you wouldn't be able to join this study.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years old or older?
- Has your doctor already decided to treat your prurigo nodularis with dupilumab?
- Can you understand and complete questionnaires?
- Have you not used dupilumab in the last 6 months?
- Are you not currently in another clinical trial that involves receiving a treatment?
What does participation involve?
If you join this study, your doctor will continue treating your prurigo nodularis with dupilumab as they normally would. Researchers will then collect information about your health, how you're using dupilumab, and how your condition changes over time. You will be asked to complete questionnaires to provide this information. The study will follow you for about 18 months, or until you decide to stop participating, or if other circumstances mean you can no longer be part of the study.
Potential risks and benefits
Locations (49)
- Medical Dermatology Specialists Site Number : 8400005Verified postcodePhoenix, United States
- Saguaro Dermatology Associates, LLC - Probity - PPDS- Site Number : 8400024Verified postcodePhoenix, United States
- Center for Dermatology Clinical Research- Site Number : 8400002Verified postcodeFremont, United States
- Halcyon Dermatology- Site Number : 8400023Verified postcodeLaguna Hills, United States
- Mission Dermatology - Rancho Santa Margarita- Site Number : 8400015Verified postcodeRancho Santa Margarita, United States
- Golden State Dermatology- Site Number : 8400014Verified postcodeWalnut Creek, United States
- Total Vein And Skin, LLC- Site Number : 8400019Verified postcodeBoynton Beach, United States
- GSI Clinical Research- Site Number : 8400017Verified postcodeMargate, United States
- Allergy Center at Brookstone Research - Centricity Research - PPDS- Site Number : 8400025Verified postcodeColumbus, United States
- Dawes Fretzin Clinical Research Group-7910 N Shadeland Ave- Site Number : 8400003Verified postcodeIndianapolis, United States
- Oakland Hills Dermatology - 3400 Auburn Rd- Site Number : 8400007Verified postcodeAuburn Hills, United States
- Derm Institute of Western Michigan- Site Number : 8400034Verified postcodeCaledonia, United States
Common questions
What is prurigo nodularis?
It's a skin condition that causes very itchy, firm bumps or lumps on the skin, often made worse by scratching.
What is dupilumab?
Dupilumab is a medicine that works by calming down parts of your immune system that can cause inflammation, helping to relieve itching and skin problems.
Why is this called an 'observational study'?
It means the researchers are just watching what happens to patients who are already taking dupilumab as part of their normal care. They aren't telling doctors how to treat patients or giving new medicines.
Will I get any special treatment in this study?
No, you will receive the same care and dupilumab treatment from your doctor that you would normally. The study just collects information about it.
How long will I be followed?
You'll be followed for about 18 months, or until you choose to leave the study.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.